TRAX
First Tracks Biotherapeutics, Inc. Ordinary Shares
Nasdaq · usd
First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) trades at $50.06 (+8.03%) as of 2:33:34 PM EST on Nov 4, 2026, +58.65% over the past month. Market cap is $1.95B, with 4.8 days to cover in short interest.
Stock performance
How First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) stock has performed from one day to one year, with its 52-week range.
- 1D
- +7.47%
- 1W
- +8.92%
- 1M
- +58.65%
- YTD
- +167.74%
- 1Y
- +167.74%
- 52-wk range
- $14.72 – $50.17
Key statistics
Today's trading snapshot for TRAX: day range, open, previous close, volume and market cap.
- Day range
- $46.09 – $50.17
- Open
- $48.01
- Prev close
- $46.34
- Volume
- 500.7K
- Market cap
- $1.95B
- Shares out
- 42.02M
8-K filings
Material corporate events First Tracks Biotherapeutics, Inc. Ordinary Shares has disclosed to the SEC on Form 8-K.
- Quarterly earningsNov 3, 2026
On November 3, 2026, First Tracks Biotherapeutics, Inc. ("First Tracks") issued a press release announcing its financial results for the three and nine months ended September 30, 2026.
- Private placementOct 20, 2026
On October 19, 2026 (the "Closing Date"), First Tracks Biotherapeutics, Inc. ... closed its previously announced private placement ... of an aggregate 6,106,870 shares ... of the Company's common stock.
- Clinical trial resultsOct 13, 2026
On October 12 2026, the Company issued a press release announcing positive topline data from the first Phase 1b cohort of ANB033 in Celiac Disease.
- Lease agreementJun 22, 2026
On June 15, 2026, First Tracks Biotherapeutics, Inc. (the "Company"), entered into a Sublease Agreement (the "Sublease") with AnaptysBio, Inc., a Delaware corporation ("AnaptysBio"), pursuant to which AnaptysBio agreed to sublease to the Company approximately 45,057 rentable square feet of space located at 10770 Wateridge Circle, San Diego, California 92121. The term of the Sublease commenced on June 15, 2026, and continues for a period of twelve (12) months from commencement.
- Acquisition consideration sharesApr 20, 2026
On the Distribution Date, in connection with the Spin-Off, the Company issued 29,100,802 shares of Common Stock to AnaptysBio in consideration for the transfer of certain entities that are part of AnaptysBio's biopharma business. After this issuance, AnaptysBio held 29,100,902 shares of Common Stock.
TRAX short interest
How heavily TRAX is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 4.8
- Short interest
- 6.96M
- Avg volume
- 1.46M
As of · reported to FINRA twice monthly.
Frequently asked questions
What is the First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) stock price today?
First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) is trading at $50.06 (+8.03% on the day) as of 2:33:34 PM EST on Nov 4, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is First Tracks Biotherapeutics, Inc. Ordinary Shares?
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a…
What is the short interest in TRAX?
As of Oct 15, 2026, TRAX has 6.96M shares short and 4.8 days to cover.
What exchange is TRAX listed on?
First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of TRAX with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a TRAX analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.